<DOC>
	<DOCNO>NCT00595231</DOCNO>
	<brief_summary>This eight week , randomize , double blind , placebo-controlled , exploratory study . Patients randomized rufinamide ( SYN111 ) receive 250 mg BID ( total daily dose 500mg ) one week dose increase 500 mg BID ( total daily dose 1000mg ) remain 7 week study . If 500 mg BID dose tolerate , one dose reduction allow .</brief_summary>
	<brief_title>Exploratory Study Evaluate Effect SYN111 ( Rufinamide ) Patients With Generalized Anxiety Disorder ( GAD )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<criteria>Outpatient 1865 Meet DSM IV criterion GAD Have moderate severe anxiety Sign IRB approve consent comply visit procedure Women childbearing potential must use acceptable method contraception Have diagnosis adjustment disorder anxiety disorder NOS Have diagnosis specific phobia Have diagnosis antisocial personality disorder Axis II Disorder Have diagnosis substance abuse disorder within 3 month study entry Have diagnosis major depressive disorder panic disorder within 6 month study entry Have diagnosis PTSD , eat disorder substance dependence disorder within 12 month study entry Have diagnosis anytime lifetime schizophrenia psychotic disorder , bipolar mood disorder , OCD , psychosurgery Require medication treat GAD study medication Failed show improvement past treatment GAD Excessively consume caffeine Are receive treatment prohibit medication Uncontrolled thyroid condition Positive urine drug screen Obese Clinically significant ECG find Participating clinical trial Clinically significant range lab value Past exposure rufinamide Pregnant nursing female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>GAD</keyword>
</DOC>